Edwards Lifesciences Corporation

(New York Stock Exchange)
Back to all articles
Bullish +60

What to Expect From Edwards Lifesciences' Next Quarterly Earnings Report

AI-generated analysis

๐Ÿฅ Edwards Lifesciences (EW), based in Irvine, California, holds a $48 billion market cap and specializes in structural heart disease and critical care technologies.

๐Ÿ“… The company is preparing to release its fiscal first-quarter 2026 earnings results in the near term.

๐Ÿ’ฐ Analysts project a Q1 2026 profit of $0.72 per share, representing a 12.5% increase from the previous year.

โš–๏ธ Historically, EW has beaten estimates in three of the last four quarters but missed forecasts on one occasion.

๐Ÿ“ˆ For fiscal 2026, expected annual EPS stands at $2.96, a 15.6% rise from $2.56 in fiscal 2025.

๐Ÿ”ฎ Long-term growth is anticipated with projected FY2027 EPS reaching $3.30, up 11.5% year over year.

๐Ÿš€ Stock performance has outpaced the S&P 500's 13.4% gains and XLV ETF returns over the past 52 weeks.

โค๏ธ Revenue momentum is driven by strong TAVR adoption and successful iterations of the SAPIEN heart valve.

๐Ÿ’ก Strategic R&D focuses on next-gen technologies like the SAPIEN M3 to help meet a $2 billion sales target by 2030.

๐Ÿ‘ Analyst consensus remains moderately bullish, with an average price target of $96.44 indicating 17.5% upside potential.

๐Ÿ“Š Of 30 analysts covering the stock, 18 recommend "Strong Buy," while 2 rate it "Moderate Buy" and 10 suggest "Hold."

Bullish Signals
  • Analysts expect EW to report a profit of $0.72 per share in the upcoming quarter, representing a 12.5% increase from the prior year's $0.64 per share.
  • For fiscal year 2027, EPS is projected to rise 11.5% year-over-year to $3.30, indicating sustained growth momentum.
  • EW stock has outperformed both the S&P 500 Index's 13.4% gains and the State Street Health Care Select Sector SPDR ETF over the past 52 weeks.
  • The company is strategically positioned to meet its $2 billion TMTT sales target by 2030 driven by strong TAVR momentum and successful SAPIEN valve iterations.
  • Analyst consensus remains moderately bullish, with 18 out of 30 analysts recommending a 'Strong Buy' rating for the stock.
  • The average analyst price target of $96.44 suggests a potential upside of 17.5% from current trading levels.
Risk Factors
  • Missing earnings forecasts on one occasion out of the last four quarters, indicating some inconsistency in meeting market expectations.
  • Out of 30 analysts covering EW stock, 10 advise a 'Hold' rating, showing more than a third are not bullish enough to recommend a strong buy.
  • The company must meet its $2 billion TMTT sales target by 2030, which represents an ambitious goal with no clear path provided if it falls short.
  • Analyst consensus is only 'Moderately Bullish' rather than strongly positive, suggesting the stock may face headwinds or competition in the structural heart disease sector.
Full Analysis
Edwards Lifesciences Corporation (EW), headquartered in Irvine, California, is a leading global structural heart innovation company with a $48 billion market capitalization. The firm specializes in providing products and technologies for structural heart disease and critical care monitoring, including tissue replacement heart valves, hemodynamic monitoring devices, and pharmaceuticals. Investors are awaiting the company's fiscal first-quarter earnings report for 2026, during which analysts project a diluted profit of $0.72 per share, representing a 12.5% increase from $0.64 per share in the year-ago quarter. Historical performance shows that Edwards has beaten consensus estimates in three of its last four quarters, while missing forecasts on one occasion. Looking beyond the immediate quarter, financial analysts anticipate EW will report full-year earnings per share (EPS) of $2.96, which would mark a 15.6% increase from $2.56 in fiscal 2025. Long-term projections suggest EPS will rise to $3.30 in fiscal 2027, an 11.5% year-over-year increase. The company has demonstrated significant outperformance relative to broader market benchmarks, gaining 15.5% over the past 52 weeks compared to the S&P 500 Indexโ€™s (SPX) 13.4% gains and surpassing returns from the State Street Health Care Select Sector SPDR ETF (XLV). This momentum is largely attributed to strong Transcatheter Aortic Valve Replacement (TAVR) progress and the successful adoption of SAPIEN valve iterations, particularly the new SAPIEN M3 designed for transseptal mitral replacement. Management's strategic focus on next-generation technologies positions Edwards to meet its $2 billion Total Medical Technologies Target by 2030. The stock carries a "Moderate Buy" rating based on consensus opinion from analysts, with 18 of the 30 coverages recommending a "Strong Buy," two advising a "Moderate Buy," and 10 suggesting a "Hold." The average analyst price target stands at $96.44, implying a potential upside of 17.5% from current levels. These earnings periods are viewed as critical opportunities for gaining deeper management insights that extend beyond standard regulatory approvals, highlighting how established healthcare firms continue to accelerate growth through blockbuster medical device innovations. *Disclaimer: Neha Panjwani did not have positions in any securities mentioned on the date of publication. All information is for informational purposes and originally published on Barchart.com.*